205 related articles for article (PubMed ID: 28373460)
1. A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
Inoue Y; Yamashita N; Tokunaga E; Tanaka K; Ueo H; Saeki H; Oki E; Yamamoto H; Maehara Y
Anticancer Res; 2017 Apr; 37(4):1917-1921. PubMed ID: 28373460
[TBL] [Abstract][Full Text] [Related]
2. [Two Cases of Unresectable/Advanced Breast Cancer with Pathological Complete Response after Combination Chemotherapy with Pertuzumab. Trastuzumab, and Docetaxel].
Tomida K; Kawai Y; Mori T; Kitamura M; Kato H; Sakai S; Shimizu T; Umeda T; Tatsumi M; Shimada K; Tani M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2435-2437. PubMed ID: 30692489
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
4. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
5. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Luminal-HER2 Advanced Breast Cancer with Liver Metastasis Showed Pathological Complete Response to the Therapy with Pertuzumab plus Trastuzumab plus Docetaxel].
Hamaoka A; Matsuda T; Konishi E; Taguchi T
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1097-100. PubMed ID: 27628551
[TBL] [Abstract][Full Text] [Related]
7. [Two Cases of Advanced HER2-Positive Locally Advanced Breast Cancer for Which Preoperative Chemotherapy with Pertuzumab, Trastuzumab, and Docetaxel Resulted in Good Response].
Ishiyama T; Yamaya H; Jinguu A; Matsumoto H
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1505-1507. PubMed ID: 33130751
[TBL] [Abstract][Full Text] [Related]
8. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.
Senda N; Yamaguchi A; Nishimura H; Shiozaki T; Tsuyuki S
Breast Cancer; 2016 Mar; 23(2):323-8. PubMed ID: 26116144
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
[TBL] [Abstract][Full Text] [Related]
13. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
[TBL] [Abstract][Full Text] [Related]
14. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Gao JJ; Tan M; Pohlmann PR; Swain SM
Clin Breast Cancer; 2017 Feb; 17(1):76-78. PubMed ID: 27692565
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
[TBL] [Abstract][Full Text] [Related]
16. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
17. [A Case of HER2-Positive Breast Cancer with Newly Diagnosed Stage IV That Responded to First-Line Pertuzumab and Trastuzumab-Based Therapy].
Yoshioka S; Hojo S; Toyoda Y; Maeura Y
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1214-1216. PubMed ID: 29394585
[TBL] [Abstract][Full Text] [Related]
18. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
Hurley J; Doliny P; Reis I; Silva O; Gomez-Fernandez C; Velez P; Pauletti G; Powell JE; Pegram MD; Slamon DJ
J Clin Oncol; 2006 Apr; 24(12):1831-8. PubMed ID: 16549824
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
Cortés J; Fumoleau P; Bianchi GV; Petrella TM; Gelmon K; Pivot X; Verma S; Albanell J; Conte P; Lluch A; Salvagni S; Servent V; Gianni L; Scaltriti M; Ross GA; Dixon J; Szado T; Baselga J
J Clin Oncol; 2012 May; 30(14):1594-600. PubMed ID: 22393084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
